Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.

Genes Cancer. 2013 Nov;4(11-12):476-85. doi: 10.1177/1947601913513268.

PMID:
24386508
[PubMed]
Free PMC Article
2.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

PMID:
23532369
[PubMed - indexed for MEDLINE]
3.

Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D.

J Invest Dermatol. 2013 Apr;133(4):1043-51. doi: 10.1038/jid.2012.401. Epub 2012 Nov 29.

PMID:
23190892
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.

Neuro Oncol. 2012 Jan;14(1):34-42. doi: 10.1093/neuonc/nor184. Epub 2011 Oct 20.

PMID:
22015595
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Akt signaling is required for glioblastoma maintenance in vivo.

Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL.

Am J Cancer Res. 2011;1(2):155-167.

PMID:
21796274
[PubMed]
Free PMC Article
6.

Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.

McKinney AJ, Holmen SL.

Chin J Cancer. 2011 Mar;30(3):153-62. Review.

PMID:
21352692
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

PMID:
21057530
[PubMed - indexed for MEDLINE]
8.

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.

VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2010 Aug;23(4):531-41. doi: 10.1111/j.1755-148X.2010.00717.x. Epub 2010 Apr 23.

PMID:
20444198
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.

Oncogene. 2010 Jan 21;29(3):335-44. doi: 10.1038/onc.2009.333. Epub 2009 Oct 26.

PMID:
19855433
[PubMed - indexed for MEDLINE]
10.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

PMID:
19422607
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL.

Cancer Res. 2009 Mar 1;69(5):1985-94. doi: 10.1158/0008-5472.CAN-08-3934. Epub 2009 Feb 24.

PMID:
19244105
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Inhibition of Marek's disease virus replication by retroviral vector-based RNA interference.

Chen M, Payne WS, Hunt H, Zhang H, Holmen SL, Dodgson JB.

Virology. 2008 Aug 1;377(2):265-72. doi: 10.1016/j.virol.2008.03.019.

PMID:
18570965
[PubMed - indexed for MEDLINE]
Free Article
13.

Inhibition of avian leukosis virus replication by vector-based RNA interference.

Chen M, Granger AJ, Vanbrocklin MW, Payne WS, Hunt H, Zhang H, Dodgson JB, Holmen SL.

Virology. 2007 Sep 1;365(2):464-72. Epub 2007 May 9.

PMID:
17493657
[PubMed - indexed for MEDLINE]
Free Article
14.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70. Epub 2007 Feb 5.

PMID:
17297468
[PubMed - indexed for MEDLINE]
15.

APC inhibits ERK pathway activation and cellular proliferation induced by RAS.

Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO, Chung KC, Surh YJ, Choi KY.

J Cell Sci. 2006 Mar 1;119(Pt 5):819-27. Epub 2006 Feb 14.

PMID:
16478791
[PubMed - indexed for MEDLINE]
Free Article
16.

Essential role for Ras signaling in glioblastoma maintenance.

Holmen SL, Williams BO.

Cancer Res. 2005 Sep 15;65(18):8250-5.

PMID:
16166301
[PubMed - indexed for MEDLINE]
Free Article
17.

Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.

Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML.

Mol Cell Biol. 2005 Jun;25(12):4946-55.

PMID:
15923613
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Essential role of beta-catenin in postnatal bone acquisition.

Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO.

J Biol Chem. 2005 Jun 3;280(22):21162-8. Epub 2005 Mar 31.

PMID:
15802266
[PubMed - indexed for MEDLINE]
Free Article
19.

Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein.

Holmen SL, Robertson SA, Zylstra CR, Williams BO.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):533-9.

PMID:
15694380
[PubMed - indexed for MEDLINE]
20.

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.

Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO.

J Bone Miner Res. 2004 Dec;19(12):2033-40. Epub 2004 Sep 13.

PMID:
15537447
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk